{
    "title": "GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11780969/GSKs-ViiV-says-study-shows-long-acting-HIV-shot-effective-Gileads-daily-pill.html",
    "date": "2023-02-22",
    "keywords": [
        "hiv",
        "viiv",
        "study",
        "injection",
        "pill",
        "cabenuva",
        "maggie",
        "treatment",
        "longacting",
        "head",
        "future",
        "dolutegravir",
        "co",
        "inc",
        "day",
        "london",
        "drugmaker",
        "division",
        "healthcare",
        "daily",
        "attention",
        "business",
        "core",
        "compound",
        "begin",
        "virus",
        "frontier",
        "pharma",
        "merck",
        "amp",
        "combination",
        "gsk",
        "loss",
        "exclusivity",
        "revenue",
        "third",
        "goal",
        "biktarvy",
        "press",
        "release",
        "status",
        "prevention",
        "research",
        "development",
        "interview",
        "studys",
        "publication",
        "point",
        "quality",
        "life",
        "disease",
        "pfizer",
        "shionogi",
        "ltd",
        "fick",
        "editing",
        "mark",
        "potter"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}